|

EMDR Treatment in PTSD Following Cardiac Events

RECRUITINGN/ASponsored by University of Zurich
Actively Recruiting
PhaseN/A
SponsorUniversity of Zurich
Started2020-11-21
Est. completion2026-11-30
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted

Summary

Cardiac events can often result in debilitating and persistent psychological symptoms. A key question involves whether optimal treatment of cardiac-induced posttraumatic stress disorder (PTSD) reduces PTSD symptoms and thereby may offset the risk of recurrent or worsening cardiovascular disease. Cardiac-induced PTSD 1) is prevalent, 2) features symptoms unique to internal ongoing somatic threat, with fears and worries that can be distinguished from PTSD resulting from external causes, 3) is persistent, 4) is associated with negative physical and emotional consequences, and 5) has not been the subject of randomized-controlled treatment trials (RCT). There is preliminary evidence suggesting that patients with cardiac-disease induced PTSD might particularly profit from EMDR. Nevertheless, this possibility has not been tested in cardiac-induced PTSD. Currently, patients with cardiac-induced PTSD are not routinely offered trauma-focused therapies, with a lack of scientific evidence likely being one major reason for this omission. If our proposed RCT shows that EMDR can be an effective treatment for patients with ACS-induced PTSD, EMDR could be routinely implemented as first-line treatment. The RCT outcomes might inform larger trials to test whether poor prognosis in terms of major adverse cardiovascular events can be improved through EMDR in patients with cardiac-induced PTSD.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age between 18-70 years
* Men or women
* STEMI (irrespective of troponin, but ST-elevation) or non-STEMI (troponin positive) at the time of the cardiac event, as verified by the cardiologist
* Diagnosis of PTSD caused by the cardiac event

Exclusion Criteria:

* Psychotic disorder, bipolar disorder, substance abuse as measured with the Mini International Neuropsychiatric Interview (M.I.N.I)
* Acute suicidal ideation as assessed with the M.I.N.I.
* Non-selective beta blockers (e.g., propranolol) during the study period
* Ongoing psychological/psychiatric treatment outside of the trial during the study period
* Visionary problems, e.g. strabismus, which does not allow adequate eye movements
* Insufficient knowledge of the German language
* Expected inability or willingness to follow the study protocol

Conditions4

Eye Movement Desensitization and ReprocessingHeart DiseaseMyocardial InfarctionPosttraumatic Stress Disorder

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.